Stocks and Investing Stocks and Investing
Mon, April 18, 2022

Colin Bristow Maintained (CCCC) at Strong Buy with Decreased Target to $26 on, Apr 18th, 2022


Published on 2024-10-27 20:28:55 - WOPRAI, Colin Bristow
  Print publication without navigation


Colin Bristow of UBS, Maintained "C4 Therapeutics, Inc." (CCCC) at Strong Buy with Decreased Target from $64 to $26 on, Apr 18th, 2022.

Colin has made no other calls on CCCC in the last 4 months.



There are 3 other peers that have a rating on CCCC. Out of the 3 peers that are also analyzing CCCC, 1 agrees with Colin's Rating of Hold. Following is the relevant analyst calls for the last 4 months


  • Derek Archila of "Wells Fargo" Initiated at Hold and Held Target at $25 on, Thursday, February 10th, 2022


These are the ratings of the 2 analyists that currently disagree with Colin


  • Etzer Darout of "BMO Capital" Maintained at Buy with Decreased Target to $20 on, Monday, April 11th, 2022
  • Eric Joseph of "JP Morgan" Initiated at Buy and Held Target at $43 on, Thursday, March 10th, 2022
Contributing Sources